User:Mr. Ibrahem/Tezepelumab
 Structural basis for inhibition of TSLP-signaling by Tezepelumab (PDB 5J13)[1] | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | thymic stromal lymphopoietin (TSLP) |
| Clinical data | |
| Trade names | Tezspire |
| Other names | MEDI9929, AMG 157, tezepelumab-ekko |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Subcutaneous |
| Legal status | |
| Legal status | |
| Chemical and physical data | |
| Formula | C6400H9844N1732O1992S52 |
| Molar mass | 144590.40 g·mol−1 |
Tezepelumab, sold under the brand name Tezspire, is a medication used for the treatment of asthma.[3][5] Specifically it is used for severe asthma, which is not controlled by other medication, in those at least 12 years old.[5] It is given by injection under the skin every 4 weeks.[5]
The most common side effects include joint pain and sore throat.[5] Other side effects may include allergic reactions.[3] While there is no evidence of harm in pregnancy, such use has not been well studied.[3] It is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), resulting in less airway inflammation.[3][5]
Tezepelumab was approved for medical use in the United States in 2021 and Europe in 2022.[3][5] In the United States it costs about 48,000 USD per year as of 2022.[6] While approved in the UK it was not yet marketed as of 2022.[6]
References[edit]
- ^ Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, et al. (April 2017). "Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma". Nature Communications. 8 (1): 14937. Bibcode:2017NatCo...814937V. doi:10.1038/ncomms14937. PMC 5382266. PMID 28368013.
- ^ "Tezspire Product information". Health Canada. 25 April 2012. Archived from the original on 1 October 2022. Retrieved 1 October 2022.
- ^ a b c d e f g h "Tezspire- tezepelumab-ekko injection, solution". DailyMed. Archived from the original on 25 December 2021. Retrieved 24 December 2021.
- ^ "Tezspire (tezepelumab) approved in the US for severe asthma". AstraZeneca (Press release). 17 December 2021. Archived from the original on 18 December 2021. Retrieved 17 December 2021.
- ^ a b c d e f g h "Tezspire EPAR". European Medicines Agency. 19 July 2022. Archived from the original on 22 September 2022. Retrieved 21 September 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b "Tezepelumab". SPS - Specialist Pharmacy Service. 16 March 2018. Archived from the original on 6 March 2022. Retrieved 24 October 2022.